Peripheral Vascular Devices Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Peripheral Vascular Devices Market Trends and Insights

Rapid Rise in Peripheral Artery & Venous Disease Prevalence

Medicare claims showed a 19% jump in lower-extremity revascularizations between 2019 and 2024, even while average length of stay fell 23%, underscoring the push for faster, device-intensive therapy. Deep-vein thrombosis incidence across OECD members increased 8% annually over 2020-2025, fueled by post-COVID sequelae and obesity. The American Heart Association positioned DVT as the third largest acute cardiovascular syndrome in its 2025 update, elevating it from a niche condition to a mainstream interventional focus.

Shift Toward Minimally-Invasive, Catheter-Based Revascularization

Open bypass volumes in the United States dropped 31% between 2015 and 2024, while percutaneous interventions rose 47%. Drug-eluting stents now deliver 78% 5-year patency in femoropopliteal disease, neutralizing the historic durability edge of surgery. Japan’s 2024 reimbursement decision on atherectomy prompted a 40% spike in procedure counts the next quarter.

Rapid Adoption of Drug-Coated Balloon Technology

Drug-coated balloons (DCBs) captured 29% of global angioplasty-balloon income in 2025. The COMPARE trial reported 83% 12-month patency with paclitaxel balloons versus 68% for uncoated options. Safety dialog continues: the FDA ordered 5-year surveillance studies and expanded mortality warnings in 2024, tempering U.S. growth but accelerating European interest in sirolimus-based alternatives.

Growth of Office-Based Labs in OECD Nations

OBLs handled 22% of U.S. peripheral interventions in 2025, translating to USD 2.1 billion in device sales at 35% lower facility cost relative to hospital outpatient departments. Germany and Australia widened OBL-eligible code lists in 2024-2025, propelling volume out of inpatient settings.

Device Reimbursement Cuts in the US & Select EU Markets

The 2026 CMS bundled-payment ceiling of USD 18,500 per 90-day PAD episode forces hospitals to secure 15-25% device discounts. Germany trimmed lower-extremity DRG weights 8% in 2025; United Kingdom guidance now limits first-line DCB use to in-stent restenosis, curbing premium-technology uptake.

Safety Concerns Over Paclitaxel-Eluting Peripherals

FDA-mandated labeling revisions in 2024 follow a meta-analysis showing a 1.4% absolute mortality rise at five years. Japan’s PMDA paused new paclitaxel clearances pending local registry data, while EU regulators require annual imaging but have stopped short of withdrawal^{[1]FDA, “Update on Treatment of Peripheral Arterial Disease With Paclitaxel-Coated Balloons and Paclitaxel-Eluting Stents,” fda.gov}.

Segment Analysis

By Device Type: Atherectomy Drives Premium Shift

Atherectomy revenue is expected to post an 8.22% CAGR between 2026-2031, the highest among device classes. The peripheral vascular devices market share for angioplasty balloons was 35.18% in 2025, but aggressive price competition from Asian generics cut average selling prices 12% compared with 2022. The peripheral vascular devices market size for atherectomy systems is projected to reach a significant revenue by 2031, alongside the calcium-heavy lesion mix and supportive coding in Japan and Australia. Directional atherectomy plus DCB achieved 81% 18-month patency in calcified vessels per the DEFINITIVE LE data set. Hospitals, however, cap usage to imaging-confirmed severe calcification because a single catheter still costs USD 2,500-3,500.

Second-tier products illustrate polarization. Thrombectomy adoption surged after FDA clearance of aspiration systems for iliofemoral DVT in 2024. Self-expanding stents edge toward commoditization, with vendors pivoting to fracture-resistant alloys and thinner strut profiles. IVC filters have declined after updated ACCP guidelines against prophylactic use, whereas guidewires and sheaths anchor low-margin but indispensable recurring revenue streams.

Note: Segment shares of all individual segments available upon report purchase

By Clinical Application: DVT Gains as PAD Matures

Peripheral arterial disease retained 45.21% revenue in 2025; nonetheless, deep-vein thrombosis procedures are forecast to grow 5.65% annually through 2031. The peripheral vascular devices market size for DVT interventions is set to expand as catheter-directed thrombectomy earns a Class IIa recommendation in the 2024 CHEST guideline^{[2]CHEST, “Antithrombotic Therapy for VTE Disease Guideline 2024,” chestnet.org} . Hospitals devote roughly 2.8 times more device spend treating Rutherford 5-6 critical-limb ischemia than claudication cases because multilevel lesions often require adjunct atherectomy and provisional stenting. Pelvic-venous-disorder work gains from dedicated stent launches, whereas acute limb ischemia volumes inch down under better systemic anticoagulation.

Cost-effectiveness remains under scrutiny. A 2025 JAMA Network Open analysis pegged catheter-directed thrombolysis at USD 12,000 per quality-adjusted life year above oral therapy, near payer thresholds. Vendors bankroll real-world registries to prove savings from avoided post-thrombotic syndrome, aiming to entrench the procedure.

By End User: ASCs Reshape Purchasing Dynamics

Hospitals controlled 60.32% of 2025 turnover, yet ambulatory surgical centers clock a 7.12% CAGR for 2026-2031—the fastest across settings. The peripheral vascular devices market share of hospitals will dip by 2031 as CMS and private payers enlarge ASC-covered code lists. Group-purchasing leverage lets ASCs pay 23% less than hospitals for comparable devices. Vendors answer with ASC-labeled SKUs that strip accessory kits and adopt consignment or per-case pricing. OBLs, a clinic subset, already capture 22% of U.S. peripheral procedures but face possible slowdowns where state boards propose tighter oversight.

Hospitals maintain dominance in complex, high-acuity cases requiring hybrid open and endovascular techniques as well as immediate surgical backup. That bifurcation steers routine femoropopliteal angioplasty to ASCs yet keeps multilevel critical-limb work inside tertiary centers.

Note: Segment shares of all individual segments available upon report purchase

Geography Analysis

North America provided 42.25% of 2025 revenue. The United States braces for tempered growth as payment caps and site-of-care migration drive negotiations that pull average device spend per case down to USD 1,800 in ASCs versus USD 2,400 in hospitals. Canada invested in cath-lab capacity, yet provincial wait times of 12 weeks restrain volume. Mexico’s private-hospital tier moves ahead with lithotripsy and limus balloons, contrasting with resource-limited public institutions.

Asia-Pacific is on track for a 7.68% CAGR. China’s peripheral vascular devices market benefits from domestic champions capturing significant market share through aggressive pricing. India’s Pradhan Mantri Swasthya Suraksha Yojana accelerates cath-lab installations beyond tier-1 metros, narrowing care disparities. Japan’s aging diabetogenic population fuels PAD prevalence, though device spend per case averages USD 1,600 amid shorter hospital stays. Australia’s 2025 OBL item numbers position it as a proving ground for next-wave sirolimus balloons.

Europe contributes sizeable absolute dollars, yet heterogenous reimbursement rules split adoption curves. Germany reimburses DCBs as first-line therapy, while the United Kingdom caps DCBs for restenosis. France green-lit orbital atherectomy in 2024. Eastern Europe, reliant on earlier-generation balloons, receives EU structural funds earmarked for cath-lab upgrades that will underpin gradual technology catch-up.